Literature DB >> 18848732

The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis.

Zehra Akpinar1, Serhat Tokgöz, Hakki Gökbel, Nilsel Okudan, Faruk Uğuz, Gülsüm Yilmaz.   

Abstract

The association of nocturnal serum melatonin levels was investigated in acute multiple sclerosis (MS) patients with major depression (MD). The sample comprised 13 patients with MD and 12 with no psychiatric disorders admitted to our clinic due to acute MS attacks. Psychiatric evaluation was performed with the Structured Clinical Interview for DSM-IV (SCD-I). The level of depressive symptoms was assessed with the Beck Depression Scale (BDS). Blood samples were taken from the patients to determine melatonin level at 03.30 h and 10.00 h before steroid treatment started. Melatonin levels were determined using the ELISA test. Nocturnal serum melatonin levels (21.2+/-17.1 pg/ml) of the patients with MD were significantly lower than those (51.5+/-18.3 pg/ml) of the patients without MD. A significant negative correlation was found between BDS scores and nocturnal serum melatonin levels. These findings suggest that a melatonin deficiency may be among the factors involved in the occurrence of depression in MS patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848732     DOI: 10.1016/j.psychres.2007.11.022

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  17 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

2.  Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Authors:  Simone Kern; Michael Geiger; Madlen Paucke; Alina Kästner; Katja Akgün; Tjalf Ziemssen
Journal:  J Mol Med (Berl)       Date:  2019-08-30       Impact factor: 4.599

Review 3.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

4.  Biological outcome measurements for behavioral interventions in multiple sclerosis.

Authors:  Anja Fischer; Christoph Heesen; Stefan M Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

Review 5.  Potential Circadian Rhythms in Oligodendrocytes? Working Together Through Time.

Authors:  Christopher S Colwell; Cristina A Ghiani
Journal:  Neurochem Res       Date:  2019-03-25       Impact factor: 3.996

6.  Effect of Treatment with Thyme Extract on Urinary Levels of Melatonin in an Experimental Autoimmune Encephalomyelitis Mouse Model.

Authors:  Merat Mahmoodi; Farnaz Sedghy; Abdollah Jafarzadeh
Journal:  Rep Biochem Mol Biol       Date:  2020-01

7.  Chronobiology of Melatonin beyond the Feedback to the Suprachiasmatic Nucleus-Consequences to Melatonin Dysfunction.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2013-03-12       Impact factor: 5.923

Review 8.  Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

Authors:  Rüdiger Hardeland
Journal:  ScientificWorldJournal       Date:  2012-05-02

Review 9.  Melatonin: buffering the immune system.

Authors:  Antonio Carrillo-Vico; Patricia J Lardone; Nuria Alvarez-Sánchez; Ana Rodríguez-Rodríguez; Juan M Guerrero
Journal:  Int J Mol Sci       Date:  2013-04-22       Impact factor: 5.923

10.  The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study.

Authors:  Abbas Ghorbani; Mehri Salari; Vahid Shaygannejad; Rasul Norouzi
Journal:  Int J Prev Med       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.